Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-04 | New | $214,025,200 | $214,025,200 | Equity Only | 06b | SEC link |
| 2024-08-14 | Amended | $117,210,000 | $20,080,000 | Equity Only | 06b | SEC link |
| 2023-12-15 | New | $97,130,000 | $97,130,000 | Equity Only | 06b | SEC link |
| 2022-10-27 | New | $168,009,933 | $168,009,933 | Equity Only | 06b | SEC link |
| 2021-10-14 | New | $91,629,837 | $91,629,837 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Chuck Baum | Director |
| Charles M. Baum | Director |
| M. Charles Baum | Director |
| Jill Carroll | Director |
| Shelley Chu | Director |
| Gary D. Glick | Director, Executive |
| Carl Gordon | Director |
| Jason Haas | Executive |
| Paulina Hill | Director |
| Lorence Kim | Director |
| Jeffrey Leiden | Director |
| Nan Li | Director |
| Carolyn Ng | Director |
| Valerie Odegard | Director |
| Ksenija Pavletic | Director |
| Ian Smith | Director |
| Lan F. Smith | Director |
| Nia Tatsis | Director |
| Timothy Walbert | Director |